Table 1.
Baseline demographic and clinical characteristics of all eligible patients.
| Characteristics | All patients
|
Patients by pT stage
|
P-value | ||
|---|---|---|---|---|---|
| pT1a (n=35) No(%) |
pT1b (n=286) No(%) |
pT1c (n=709) No(%) |
|||
| Age, years | |||||
| Median | 54 | 49 | 51 | 55 | |
| Range | (26–81) | (30–70) | (28–76) | (26–81) | 0.002 |
|
| |||||
| Race | |||||
| White | 799(77.5) | 26(74.3) | 226(79) | 546(77) | |
| Hispanic | 129(12.5) | 5(14.3) | 29(10.1) | 95(13.4) | |
| Black | 50(4.8) | 0 | 1(<1) | 6(<1) | |
| Asian | 46(4.5) | 4(11.4) | 16(5.6) | 26(3.7) | |
| Other | 7(<1) | 0 | 1(<1) | 6(<1) | 0.165† |
|
| |||||
| Menopausal status | |||||
| Premenopausal | 364(35.5) | 14(40) | 111(39.1) | 239(33.9) | |
| Postmenopausal | 661(64.5) | 21(60) | 173(60.9) | 467(66.1) | |
| Unknown | 6 | 0 | 2 | 3 | 0.245 |
|
| |||||
| Pathological stage | |||||
| IA | 984(95.4) | 28(80) | 253(88.5) | 626(88.3) | |
| IB | 47(4.6) | 7(20) | 33(11.5) | 83(11.7) | 1.000 |
|
| |||||
| Histological grade | |||||
| 1 | 254(29.6) | 14(50) | 82(33.5) | 157(26.9) | |
| 2 | 460(53.6) | 11(39.3) | 131(53.5) | 318(54.5) | |
| 3 | 144(16.8) | 3(10.7) | 32(13.1) | 109(18.7) | |
| Unknown | 173 | 7 | 41 | 125 | 0.024 |
|
| |||||
| Nuclear grade | |||||
| 1 | 151(16.8) | 10(31.3) | 38(15.2) | 103(16.7) | |
| 2 | 580(64.5) | 18(56.2) | 165(66.3) | 396(64.2) | |
| 3 | 168(18.7) | 4(12.5) | 46(18.5) | 118(19.1) | |
| Unknown | 132 | 3 | 37 | 92 | 0.293 |
|
| |||||
| LVI | |||||
| Negative | 858(87.1) | 30(100) | 238(88.1) | 589(86.1) | |
| Positive | 127(12.9) | 0 | 32(11.9) | 95(13.9) | |
| Unknown | 46 | 5 | 16 | 25 | 0.044 |
|
| |||||
| Proliferation index (Ki67 expression) | |||||
| Median | 10 | 10 | 10.5 | 10 | |
| Range | (0–91) | (1–62) | (1–81) | (0–91) | 0.603 |
|
| |||||
| ER (%) | |||||
| Median | 95 | 95 | 94 | 95 | |
| Range | (10–100) | (20–100) | (10–100) | (10–100) | 0.344 |
|
| |||||
| PR (%) | |||||
| Median | 80 | 88 | 80 | 80 | |
| Range | (0–100) | (0–100) | (0–100) | (0–100) | 0.989 |
Abbreviations: ER, estrogen receptor; LVI, lymphovascular invasion; PR, progesterone receptor.
†
P-value when comparing stages (T1a, T1b, T1c) among asian, black, spanish and white only.